Shanghai Allist Pharmaceuticals Co., Ltd. News

Alex (688578): Continued rapid release of vometinib, foreign cooperation reserves future pipelines

china merchantsOct 27 14:51

Alice (688578): Q3 revenue and profit both exceeded expectations, overseas clinical trials are about to progress

zhongtai securitiesOct 25 00:00

Alex (688578): Strong commercialization drives revenue and profits continue to exceed expectations, strong empirical evidence supports a long product life cycle

zhongtai securitiesSep 26 00:00

Alice (688578): R&D progressed smoothly

Aug 22 12:51

Alice (688578): Continued expansion of core products and rapid growth in performance

Aug 21 18:31

Alice (688578): Continuous release of vometinib, rich pipeline through internal research and external induction

Aug 20 00:00

Alice (688578): Continued release of core products

May 13 14:31

Alice (688578): Volmetinib dosage is rapidly monitoring progress in the research pipeline

Apr 26 00:00

Alice (688578): Continued rapid release of vometinib in overseas EX20INS NSCLC first-tier markets is worth looking forward to

Oct 27, 2023 15:06

Alice (688578): Accelerating sales volume, driving high profit growth, deepening global clinical layout

Industrial SecuritiesOct 27, 2023 07:22

Alice (688578): Rapid dosage of vumetinib drives rapid growth in revenue and profit

Oct 25, 2023 00:00

Alice (688578): High net profit growth in Q3 and continued dosage of vumetinib after being included in health insurance

Sep 27, 2023 19:32

Alice (688578): Increased net revenue and profit, expansion of metinib indications and efficient promotion

華金證券Sep 12, 2023 00:00

Alice (688578): Commercial rapid release

財通證券Sep 3, 2023 00:00

Alice (688578) 2023 Interim Report Review: Commercial performance is impressive, and the prospects for vumetinib are promising

中信證券Sep 1, 2023 00:00

Alice (688578): Rapid release of vumetinib, 20 exon insertion indications, can be expected in the future

招商證券Aug 30, 2023 13:36

Alice (688578) 2023 semi-annual report review: sales volume performance exceeds expectations EXON20 helps improve global space

興業證券Aug 29, 2023 00:00

Alex (688578): Volmetinib has successfully commercialized 20 exon insertion indications to further open up space

招商證券Jun 29, 2023 00:00

Iris (688578): Rapid Dosage of Volmetinib Expands Indications to Expand Space

海通證券May 6, 2023 00:00

Iris (688578) 2022 Annual Report and 2023 Quarterly Report Review: Rapid Dosage of Volmetinib opens up space for international layout

興業證券May 3, 2023 00:00